Welcome Wondros Family and
Friends! We are beta testing and need
your help improving this product.
Share Feedback
Information provided by:
Temple University
Last updated:
05/26/2021
Trial identifier:
NCT04530474
DisclaimerBrief summary:
Covid 19, a novel coronavirus, causes infection that, while mild to moderate in many people, can lead to severe disease in a significant portion. Currently, it is expected that the majority, 81%, of patients with COVID-19 will have mild to moderate disease, with 14% having more severe disease (2). There exists a number of candidate drugs that may inhibit SARS-CoV-2 infection or progression of disease. Simple, safe and low-cost strategies that may be the best solution to inhibit infection and limit transmission and spread of infection. Ivermectin is a drug initially synthesized and used as an anthelmintic. It has been found to have activity against several RNA viruses such as the SARS-CoV-2 by mechanisms that inhibit importin α/β-mediated nuclear transport that may prevent viral proteins from entering the nucleus to alter host cell function. A recent in vitro study showed that a single dose of ivermectin could kill COVID-19 in vitro within 48 hours. A recent multi-continent retrospective study of 1,400 patients demonstrated an association of ivermectin use with lower in-hospital mortality 1.4% versus 8.5%. Given these findings and its safety profile, cost and ease of administration, Ivermectin warrants study as a potential treatment to prevent progression of COVID 19 infection.
Glossary term:
Glossary term:
Glossary term:
Glossary term:
Glossary term:
Glossary term:
Glossary term:
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
Glossary term:
April 01, 2021
Glossary term:
June 30, 2021
Glossary term: